Tikvah Therapeutics and Chakra Biotech Pte. Ltd. Establish Collaboration to Accelerate the Development of Novel Antipsychotic Compounds
ATLANTA and SINGAPORE, Sept. 5, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, and Chakra Biotech Pte. Ltd., a drug discovery and development company focusing on central nervous system disorders, today announced a collaboration and option agreement designed to advance and accelerate the development of four compounds targeted at a broad range of psychiatric conditions, including schizophrenia and bipolar disorder from Chakra Biotech Pte. Ltd.'s developmental pipeline. These compounds have shown robustly positive results in the chakragati (ckr) mouse model, a patented transgenic mouse model for dopamine dysfunction that has been validated as a model for screening antipsychotic compounds.